Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) (HD2000)
This study has been completed.
Sponsored by: Gruppo Italiano Studio Linfomi
Information provided by: Gruppo Italiano Studio Linfomi
ClinicalTrials.gov Identifier: NCT00443677
  Purpose

The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.


Condition Intervention Phase
Advanced Hodgkin Disease
 Drug: COPPEBVCAD vs BEACOPP vs ABVD
 Phase III

MedlinePlus related topics: Hodgkin's Disease
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

Further study details as provided by Gruppo Italiano Studio Linfomi:

Primary Outcome Measures:
  • To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens

Secondary Outcome Measures:
  • To compare the results in terms of response, failure free survival and relapse free survival of the three regimens

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of Hodgkin disease
  • Clinical stage IIB, III, IV
  • No prior treatment for Hodgkin disease or other malignancy
  • Age 18-65 year
  • Good cardiac, pulmunar, renal and hepatic function
  • Performance status 0-3 (Karnofsky 100- 40)
  • Written Informed Consent

Exclusion Criteria:

  • HIV positivity
  • Large cell, anaplastic, CD30+ lymphoma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00443677

Sponsors and Collaborators
Gruppo Italiano Studio Linfomi
Investigators
Principal Investigator: Paolo Gobbi, MD GISL
Principal Investigator: Emilio Iannitto, MD GISL
Principal Investigator: Giuseppe Polimeno, MD GISL
  More Information

Study ID Numbers: HD2000
Study First Received: March 5, 2007
Last Updated: March 5, 2007
ClinicalTrials.gov Identifier: NCT00443677  
Health Authority: Italy: Ethics Committee

Study placed in the following topic categories:
Lymphatic Diseases
Hodgkin's disease
Immunoproliferative Disorders
Hodgkin lymphoma, adult
 Lymphoproliferative Disorders
Lymphoma
Hodgkin Disease

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services